Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus OMNIPAQUE 210.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus OMNIPAQUE 210.
CONRAY 43 vs OMNIPAQUE 210
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Radiopaque contrast agent that contains iodine, which attenuates X-rays and provides radiographic visualization of vascular structures and organs. It does not have a pharmacological mechanism of action.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intravascular administration: 50-150 mL (10-30 g iodine) as bolus or infusion, based on procedure (CT, angiography, urography). Intravenous infusion for CT: 100-200 mL at 1-3 mL/sec.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). In neonates, half-life is 6-12 hours due to immature renal function.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal: ~95% unchanged within 24 hours via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent